Fellows Detail

Professor Wayne Hall AM, FAHMS

BSc (hons), PhD (UNSW)

Elected: 2002

Discipline: Psychology

Specialisation: Addiction, Public Health, Epidemiology, Ethics, Social Policy, Mental Health, Biotechnology, Public Policy.

Profile

Professor Wayne Hall  is the Professor and Inaugural Director of the Centre for Youth Substance Abuse Research at the University of Queensland. He also has visiting Professorial appointments at the University of Queensland Centre for Clinical Research, the National Drug and Alochol Researech Centre, UNSW, the Natiopnal Addiction Centre, Kings College London and the London School of Hygiene and Tropical Medicine. He is researching the public policy and ethical implications of:

  • genetics and neuroscience research on addictive behaviour and mental disorders
  • new biotechnologies that aim to improve human health.

He was formerly an NHMRC Australia Fellow and Professorial Research Fellow at the University of Queensland Centre for Clinical Research (2010-2013), Professor of Public Health Policy in the School of Population Health (2005-2009) and Director of the Office of Public Policy and Ethics at the Institute for Molecular Bioscience at UQ (2001-2005). He was Executive Director and Professor at the National Drug and Alcohol Research Centre at the University of New South Wales (1994-2001). He has also held appointments in the Medical Schools of Universities of Western Australia (1983-1986) and New South Wales (1986-1988) where he introduced the teaching of bioethics into the undergraduate medical curriculum. He has been an Adviser to the World Health Organization on: the health implications of cannabis use (1993-1996); drug substitution treatment (1995-6); the contribution of illicit drug use to the Global Burden of Disease (2000-2002); the ethics of risk management (2001), vaccines against drug addiction (2001) and neuroscience research on the addictions (2002). He is a Member of the WHO Expert Advisory Panel on Drug Dependence and Alcohol Problems. In 2003 he was identified by the Institute for Scientific Analysis, as a “Highly Cited Author” in social science general, “comprising less than one half of one percent of all publishing researchers – in the last two decades” See http://isihighlycited.com

Publications

  • Books

     

  • Carter A, Hall WD, Illes J, eds. Addiction neuroethics: The ethics of addiction neuroscience research and treatment. Amsterdam: Elsevier, 2012.
  • Teesson M, Hall WD, Proudfoot H, Degenhardt L. Addictions, 2nd edn. Hove: Psychology Press, 2012.
  • Carter A, Hall WD. Addiction neuroethics: The promises and perils of neuroscience research on addiction. Cambridge: Cambridge University Press, 2012.
  • Room R, Fischer B, Hall WD, Lenton S, Reuter P. Cannabis policy: Moving beyond stalemate. Oxford: Oxford University Press, 2010.
  • Hall WD, Pacula RL. Cannabis use and dependence: public health and public policy. Cambridge: Cambridge University Press, 2003.
  • Teesson M, Degenhardt L, Hall WD. Addictions. Hove: Psychology Press, 2002.

Papers

  • Degenhardt L, Coffey C, Romaniuk H, Swift W, Carlin J, Hall WD, Patton G. The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction 2013; 108:124-33.
  • Meurk CS, Carter A, Hall WD, Lucke J. Public understandings of addiction: Where do neurobiological explanations fit? Neuroethics 2013; 10.1007/s12152-013-9180-1: February 15.
  • Bell S, Carter A, Mathews R, Gartner C, Lucke J, Hall WD. Views of addiction neuroscientists and clinicians on the clinical impact of a ‘brain disease model of addiction’. Neuroethics 2013; 10.1007/s12152-013-9177-9: January 19.
  • Bell S, Partridge B, Lucke J, Hall WD. Australian university students’ attitudes towards the acceptability and regulation of pharmaceuticals to improve academic performance. Neuroethics 2013; 6:197-205.
  • Carter A, Hall WD. Ethical implications of research on craving. Addictive Behaviors 2013; 38:1593-9.
  • Forlini C, Hall WD, Maxwell B, Outram SM, Reiner PB, Repantis D, Schermer M, Racine E. Navigating the enhancement landscape. Embo Reports 2013; 14:123-28.
  • Hall WD, Carter A. Advocates need to show compulsory treatment of opioid dependence is effective, safe and ethical. Bulletin of the World Health Organization 2013; 91:146-46.
  • Lai FY, Bruno R, Hall WD, Gartner C, Ort C, Kirkbride P, Prichard J, Thai PK, Carter S, Mueller JF. Profiles of illicit drug use during annual key holiday and control periods in Australia: wastewater analysis in an urban, a semi-rural and a vacation area. Addiction 2013; 108:556-65.
  • Morphett K, Lucke J, Gartner C, Carter A, Meurk C, Hall WD. Public attitudes toward the treatment of nicotine addiction. Nicotine & Tobacco Research 2013; 10.1093/ntr/ntt037: March 18.
  • Shand FL, Campbell G, Hall WD, Lintzeris N, Cohen M, Degenhardt L. Real-time monitoring of Schedule 8 medicines in Australia: evaluation is essential. Medical Journal of Australia 2013; 198:80-81.
  • Sara G, Burgess P, Malhi GS, Whiteford H, Hall WD. Differences in associations between cannabis and stimulant disorders in first admission psychosis. Schizophrenia Research 2013; 10.1016/j.schres.2013.04.017:April 15.
  • Meltzer EC, Hall WD, Fins JJ. Error and bias in the evaluation of prescription opioid misuse: Should the FDA regulate clinical assessment tools? Pain Medicine 2013; 10.1111/pme.12099: April 19.
  • Hall WD, Carter A. Anticipating possible policy uses of addiction neuroscience research. Drugs: Education, Prevention, and Policy 2013; 20:249-57.
  • Ambermoon P, Carter A, Hall WD, Dissanayaka N, O’Sullivan J. Compulsive use of dopamine replacement therapy: A model for stimulant drug addiction? (For Debate). Addiction 2012; 107:241-47
  • Gartner C, Barendregt J, Wallace A, Hall WD. Would vaccination against nicotine be a cost-effective way to prevent smoking uptake in adolescents? Addiction 2012; 107:801-9.
  • Hall WD, Babor T, Edwards G, Laranjeira R, Marsden J, Miller P, Obot I, Petry N, Thamarangsi T, West R. Compulsory detention, forced detoxification and enforced labour are not ethically acceptable or effective ways to treat addiction (Editorial). Addiction 2012; 107:1891-93.
  • Hall WD, Prichard J, Kirkbride P, Bruno R, Thai P, Gartner C, Lai F, Ort C, Mueller J. An analysis of ethical issues in using wastewater analysis to monitor illicit drug use. Addiction 2012; 107:1767-73.
  • Lucke J, Hall WD. Under what conditions is it ethical to offer incentives to encourage drug-using women to use long-acting forms of contraception? (For Debate). Addiction 2012; 107:1036-41.
  • Mathews R, Hall WD, Carter A. Direct-to-consumer genetic testing for addiction susceptibility: A premature commercialisation of doubtful validity and value (For debate). Addiction 2012; 107:2069-74.
  • Bell S, Lucke JC, Hall WD. Lessons for enhancement from the history of cocaine and amphetamine use. American Journal of Bioethics – Neuroscience 2012; 3:24-29.
  • Partridge B, Lucke J, Hall WD. A comparison of attitudes toward cognitive enhancement and legalized doping in sport in a community sample of Australian adults. American Journal of Bioethics – Primary Research 2012; 3:81-86.
  • Partridge B, Lucke J, Hall WD. Public attitudes towards the acceptability of using drugs to treat depression and ADHD. Australian and New Zealand Journal of Psychiatry 2012; 46:958-65.
  • Sara G, Burgess P, Harris M, Malhi G, Whiteford H, Hall WD. Stimulant use disorders: Characteristics and comorbidity in an Australian population sample. Australian and New Zealand Journal of Psychiatry 2012; 46:1173-81.
  • Teesson M, Slade T, Swift W, Mills K, Memedovic S, Mewton L, Grove R, Newton N, Hall WD. Prevalence, correlates and comorbidity of DSM-IV Cannabis Use and Cannabis Use Disorders in Australia. Australian and New Zealand Journal of Psychiatry 2012; 46:1182-92.
  • Gartner C, Scollo M, Marquart L, Mathews R, Hall WD. Analysis of national data shows mixed evidence of hardening among Australian smokers. Australian and New Zealand Journal of Public Health 2012; 36:408-14.
  • Hall WD. Driving while under the influence of cannabis (Editorial). British Medical Journal 2012; 344:e595.
  • Calabria B, Swift W, Slade T, Hall WD, Copeland J. The perceived health risks of cannabis use in an Australian household survey. Drug and Alcohol Review 2012; 31:809-12.
  • Hall WD. What place, if any, does information on putative cardioprotective effects of moderate alcohol use have in safer drinking guidelines? (Commentary). Drug and Alcohol Review 2012; 31:194-7.
  • Lee N, Carter A, Owen N, Hall WD. The neurobiology of overeating: Treating overweight individuals should make use of neuroscience research, but not at the expense of population approaches to diet and lifestyle (Science and Society). EMBO Reports (European Molecular Biology Organization) 2012; 13:785-90.
  • Douglas H, Hammill J, Russell E, Hall WD. Judicial views of foetal alcohol spectrum disorder in Queensland’s criminal justice system. Journal of Judicial Administration 2012; 21:178-88.
  • Degenhardt L, Hall WD. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012; 379:55-70.
  • Gartner C, Hall WD, Borland R. How should we regulate smokeless tobacco products and e-cigarettes? (Perspectives). Medical Journal of Australia 2012; 197:611-12.
  • Hunter EM, Gynther BD, Anderson CJ, Onnis LA, Nelson JR, Hall WD, Baune BT, Groves AR. Psychosis in Indigenous populations of Cape York and the Torres Strait. Medical Journal of Australia 2012; 196:133-5.
  • Haynes AS, Derrick GE, Redman S, Hall WD, Gillespie JA, Chapman S, Sturk H. Identifying trustworthy experts: How do policymakers find and assess public health researchers worth consulting or collaborating with? PLoS ONE (Public Library of Science) 2012; 7:e32665.
  • Leung J, Gartner C, Hall WD, Lucke J, Dobson A. A longitudinal study of the bi-directional relationship between tobacco smoking and psychological distress in a community sample of young Australian women. Psychological Medicine 2012; 42:1273-82.
  • Douglas H, Hammil J, Russell A, Hall WD. The importance of foetal alcohol spectrum disorder for criminal law practice: Views of Queensland criminal lawyers. Queensland Lawyer 2012; 32:153-64.
  • Teesson M, Farrugia P, Mills K, Hall WD, Baillie A. Alcohol, tobacco, and prescription drugs: The relationship with illicit drugs in the treatment of substance users. Substance Use & Misuse 2012; 47:963-71.
  • Gartner CE, Hall WD. Is the socioeconomic gap in childhood exposure to secondhand smoke widening or narrowing? Tobacco Control 2012; 10.1136/tobaccocontrol-2011-050297:March 30.
  • Prichard J, Lai FY, Kirkbride P, Bruno R, Ort C, Carter S, Hall WD, Gartner C, Thai P, Mueller J. Measuring drug use patterns in Queensland through wastewater analysis. Trends & Issues in Crime and Criminal Justice 2012; 442:8p.
  • Vos T, Flaxman A, Naghavi M, Lozano R, Michaud C, …, Hall WD, …, Lopez A, Murray C. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2163-96.
  • Murray C, Vos T, Lozano R, Naghavi M, Flaxman A, …, Hall WD, …, Lopez A. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2197-223.
  • Lim S, Vos T, Flaxman A, Danaei G, Shibuya K, …, Hall WD, …, Lopez A, Murray C, Ezzati M. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2224-60.
  • Degenhardt L, Singleton J, Calabria B, McLaren J, Kerr T, Mehta S, Kirk G, Hall WD. Mortality among cocaine users: A systematic review of cohort studies. Drug and Alcohol Dependence 2011; 117:88-95.
  • Randall D, Degenhardt L, Vajdic C, Burns L, Hall WD, Law M, Butler T. Increasing cancer mortality among opioid-dependent persons in Australia: A new public health challenge for a disadvantaged population. Australian and New Zealand Journal of Public Health 2011; 35:220-25.
  • Mathews R, Hall WD, Vos T, Patton G, Degenhardt L. What are the major drivers of prevalent disability burden in young Australians? Medical Journal of Australia 2011; 194:232-35.
  • Hollingworth S, Rush A, Hall WD, Eadie M. Utilization of anti-Parkinson drugs in Australia: 1995-2009. Pharmacoepidemiology and Drug Safety 2011; 20:450-56.
  • Hall WD, Fischer B, Lenton S, Reuter P, Room R. Making space for cannabis policy experiments. Addiction 2011; 106:1192-93.
  • Fischer B, Jeffries V, Hall WD, Room R, Goldner E, Rehm J. Lower Risk Cannabis Use Guidelines for Canada (LRCUG): A narrative review of evidence and recommendations. Canadian Journal of Public Health 2011; 102:324-27.
  • Hollingworth S, Lie D, Siskind D, Byrne G, Hall WD, Whiteford H. Psychiatric drug prescribing in elderly Australians: time for action. Australian and New Zealand Journal of Psychiatry 2011; 45:705-08.
  • Pham B, Hall WD, Hill P. Indirect evidence of the contribution of prenatal sex selection practices to the high sex ratio at birth in Vietnam. Journal of Population Research 2011; 28:293-99.
  • Ambermoon P, Carter A, Hall WD, Dissanayaka N, O’Sullivan J. Impulse control disorders in patients with Parkinson’s disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction 2011; 106:283-93.
  • Carter A, Hall WD. Proposals to trial deep brain stimulation to treat addiction are premature (Editorial). Addiction 2011; 106:235-37.
  • Hall WD, Lucke JC. Untested assumptions about putative neuroenhancement. Addiction 2011; 106:1190-91.
  • Martire KA, Mattick RP, Doran CM, Hall WD. Cigarette tax and public health: What are the implications of financially stressed smokers for the effects of price increases on smoking prevalence? Addiction 2011; 106:622-30.
  • Lucke JC, Bell S, Partridge B, Hall WD. Deflating the neuroenhancement bubble. American Journal of Bioethics – Neuroscience 2011; 2:38-43,
  • Leung J, Gartner C, Dobson A, Lucke J, Hall WD. Psychological distress is associated with tobacco smoking and quitting behaviour in the Australian population: Evidence from national cross-sectional surveys. Australian and New Zealand Journal of Psychiatry 2011; 45:170-78.
  • Hall WD, Degenhardt L. Cannabis and the increased incidence and persistence of psychosis (Editorial). British Medical Journal 2011; 342:511-12.
  • Hall WD, Gartner C. Ethical and policy issues in using vaccines to treat and prevent cocaine and nicotine dependence. Current Opinion in Psychiatry 2011; 24:191-96.
  • Degenhardt L, Bucello C, Calabria B, Nelson P, Roberts A, Hall WD, Lynskey M, Wiessing L. What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. Drug and Alcohol Dependence 2011; 117:85-101.
  • Lucke J, Bell S, Partridge B, Hall WD. Academic doping or Viagra for the brain? The history of recreational drug use and pharmacological enhancement can provide insight into these uses of neuropharmaceuticals (Science and Society: Outlook). EMBO Reports (European Molecular Biology Organization) 2011; 12:197-201.
  • Hall WD, Carter A. Is deep brain stimulation a prospective “cure” for addiction? F1000 Medicine Reports 2011; 3:10.3410/M3-4.
  • Partridge B, Lucke J, Bartlett H, Hall WD. Public attitudes towards human life extension by intervening in ageing. Journal of Aging Studies 2011; 25:73-83.
  • Prichard J, Ort C, Bruno R, Gartner C, Kirkbride P, Hall WD, Lai FY, Carter S, Thai P, Mueller J, Salina A. Developing a method for site-specific wastewater analysis: Implications for prisons and other agencies with an interest in illicit drug use. Journal of Law, Information and Science 2011; 20:15-27.
  • Hall WD, Chikritzhs T. The Australian alcopops tax revisited (Comment). Lancet 2011; 377:1136-37.
  • Hall WD, Farrell M. Minimising the misuse of oxycodone and other pharmaceutical opioids in Australia (Editorial). Medical Journal of Australia 2011; 195:248-49.
  • Mathews R, Hall WD, Gartner C. Depression and psychological distress in tobacco smokers and people with cannabis dependence in the National Survey of Mental Health and Wellbeing. Medical Journal of Australia 2011; 195:S12-15.
  • Haynes AS, Gillespie JA, Derrick GE, Hall WD, Redman S, Chapman S, Sturk H. Galvanizers, guides, champions, and shields: the many ways that policymakers use public health researchers. Milbank Quarterly 2011; 89:564-98.
  • Collins P, Patel V, Joestl S, March D, Insel T, …, Hall WD, …, Walport M. Grand challenges in global mental health: A consortium of researchers announces here research priorities for improving the lives of peaople with mental illness around the world, and calls for urgent action and investment (Comment). Nature 2011; 475:27-30.
  • Boot B, Partridge B, Hall WD. Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people. Neurocase 2011; 18:181-4.
  • Carter A, Ambermoon P, Hall WD. Drug-induced impulse control disorders: A prospectus for neuroethical analysis. Neuroethics 2011; 4:91-102.
  • Carter A, Bell E, Racine E, Hall WD. Ethical issues raised by proposals to treat addiction using deep brain stimulation. Neuroethics 2011; 4:129-42.
  • Derrick G, Haynes A, Chapman S, Hall WD. The association between four citation metrics and peer rankings of research influence of Australian researchers in six fields of public health. PLoS ONE (Public Library of Science) 2011; 6:e18521.
  • Partridge B, Bell S, Lucke JC, Yeates S, Hall WD. Smart drugs “as common as coffee”: Media hype about neuroenhancement. PLoS ONE (Public Library of Science) 2011; 6:e28416.
  • Haynes AS, Derrick GE, Chapman S, Redman S, Hall WD, Gillespie J, Sturk H. From “our world” to the “real world”: Exploring the views and behaviour of policy-influential Australian public health researchers. Social Science & Medicine 2011; 72:1047-55.
  • Lai FY, Ort C, Gartner C, Carter S, Prichard J, Kirkbride P, Bruno R, Hall WD, Eaglesham G, Mueller JF. Refining the estimation of illicit drug consumptions from wastewater analysis: Co-analysis of prescription pharmaceuticals and uncertainty assessment. Water Research 2011; 45:4437-48.
  • Hall WD, Lucke J. The enhancement use of neuropharmaceuticals: More scepticism and caution needed. Addiction 2010; 105:2041-43.
  • Partridge B, Lucke J, Hall WD. Listening to public concerns about human life extension (Outlook). EMBO Reports (European Molecular Biology Organization) 2010; 11:735-37.
  • Lucke J, Herbert D, Partridge B, Hall WD. Anticipating the use of life extension technologies:  Possible pointers from the adoption of assisted reproductive technologies. EMBO Reports (European Molecular Biology Organization) 2010; 11:334-38.
  • Hall WD, Lucke J. Legally coerced treatment for drug using offenders: ethical and policy issues. Crime and Justice Bulletin (BOSCAR, NSW Bureau of Crime Statistics and Research) 2010; 144:12p.
  • McLaren J, Silins E, Hutchinson D, Mattick R, Hall WD. Assessing evidence for a causal link between cannabis and psychosis: A review of cohort studies. International Journal of Drug Policy 2010; 21:10-19.
  • Calabria B, Degenhardt L, Hall WD, Lynskey M. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug and Alcohol Review 2010; 29:318-30.
  • Teesson M, Hall WD, Slade T, Mills K, Grove R, Mewton L, Baillie A, Haber P. Prevalence and correlates of DSM-IV alcohol abuse and dependence in Australia: Findings of the 2007 National Survey of Mental Health and Wellbeing. Addiction 2010; 105:2085-94.
  • Hollingworth S, Siskind D, Nissen L, Robinson M, Hall WD. Patterns of antipsychotic medication use in Australia, 2002-2007. Australian and New Zealand Journal of Psychiatry 2010; 44:372-77.
  • Strang J, Hall WD, Hickman M, Bird S. Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): Analyses using OD4 index in England and Scotland. British Medical Journal 2010; 341:c4851.
  • Doran C, Hall WD, Shakeshaft A, Vos T, Cobiac L. Alcohol policy reform in Australia: What can we learn from the evidence? (For debate). Medical Journal of Australia 2010; 192:468-70.
  • Calabria B, Doran C, Vos T, Shakeshaft A, Hall WD. Epidemiology of alcohol-related burden of disease among Indigenous Australians. Australian and New Zealand Journal of Public Health 2010; 34:S47-51.
  • Calabria B, Degenhardt L, Briegleb C, Vos T, Hall WD, Lynskey M, Callaghan B, Rana U, McLaren J. Systematic review of prospective studies investigating “remission” from amphetamine, cannabis, cocaine or opioid dependence. Addictive Behaviors 2010; 35:741-49.
  • Hall WD, Mathews R, Morley K. Being more realistic about the public health impact of genomic medicine (Policy forum). PLoS Medicine (Public Library of Science) 2010; 7:e1000347.
  • Hall WD, Wallace A, Cobiac L, Doran C, Vos T. How can we reduce alcohol-related road crash deaths among young Australians? (For debate). Medical Journal of Australia 2010; 192:464-66.
  • Gartner C, Jimenez-Soto E, Borland R, O’Connor R, Hall WD. Are Australian smokers interested in using low-nitrosamine smokeless tobacco for harm reduction? Tobacco Control 2010; 19:451-56.
  • Mathews R, Hall WD, Gartner C. Is there evidence of ‘hardening’ among Australian smokers between 1997 and 2007? Analyses of the Australian National Surveys of Mental Health and Well-Being. Australian and New Zealand Journal of Psychiatry 2010; 44:1132-36.
  • Gartner C, Chapman S, Hall WD, Wakefield M. Why we need tobacco sales data for good tobacco control (Editorial). Medical Journal of Australia 2010; 192:3-4.
  • Roxburgh A, Hall WD, Degenhardt L, McLaren J, Black E, Copeland J, Mattick R. The epidemiology of cannabis use and cannabis-related harm in Australia, 1993-2007. Addiction 2010; 105:1071-79.
  • Hall WD. What are the policy lessons of National Alcohol Prohibition in the United States, 1920-1933? (Addiction history). Addiction 2010; 105:1164-73.
  • Chikritzhs T, Allsop S, Moodie A, Hall WD. Per capita alcohol consumption in Australia: Will the real trend please step forward? Medical Journal of Australia 2010; 193:594-97.
  • Gartner C, Hall WD. Smokeless tobacco products: Unrecognised regulatory and policy opportunities (Editorial). Drug and Alcohol Review 2010; 29:119-20.
  • Macdonald S, Hall WD, Roman P, Stockwell T, Coghlan M, Nesvaag S. Testing for cannabis in the work-place: A review of the evidence. Addiction 2010; 105:408-16.
  • Smith A, Tett S, Hall WD. The contribution of injecting drug users in Sydney, Melbourne and Brisbane to rising benzodiazepine use in Australia, 2000 to 2006. Australian and New Zealand Journal of Public Health 2010; 34:315-19.
  • Hall WD. What would evidence-informed drug policies look like? (Editorial). Addiction 2010; 105:1135-36.
  • Liberman J, O’Brien M, Hall WD, Hill D. Ending inequities in access to effective pain relief? (Commentary on ‘Providing paediatric palliative care in Kenya’). Lancet 2010; 376:856-57.
  • Freeman B, Gartner C, Hall WD, Chapman S. Forecasting future tobacco control policy: Where to next? Australian and New Zealand Journal of Public Health 2010; 34:447-50.
  • Pham B, Rao C, Adair T, Hill P, Hall WD. Assessing the quality of data for analysing the sex ratio at birth in Viet Nam. Asian Population Studies 2010; 6:263-87.
  • Hall WD, Fischer B. Harm reduction policies for cannabis. In: Rhodes T, Hedrich D, eds. Harm reduction: Evidence, impacts and challenges EMCDDA Scientific Monograph. Lisbon: European Monitoring Centre for Drugs and Drug Addiction, 2010: 235-51.
  • Gartner C, Hall WD, McNeill A. Harm reduction policies for tobacco. In: Rhodes T, Hedrich D, eds. Harm reduction: Evidence, impacts and challenges EMCDDA Scientific Monograph. Lisbon: European Monitoring Centre for Drugs and Drug Addiction, 2010: 255-73.
  • Partridge B, Lucke J, Bartlett H, Hall WD. Ethical, social, and personal implications of extended human lifespan identified by members of the public. Rejuvenation Research 2009; 12:351-57.
  • Underwood M, Bartlett H, Partridge B, Lucke J, Hall WD. Community perceptions on the significant extension of life: An exploratory study among urban adults in Brisbane, Australia. Social Science & Medicine 2009; 68:496-503.
  • Lucke J, Diedrichs P, Partridge B, Hall WD. Anticipating the anti-ageing pill: Lessons from the history of the oral contraceptive pill and hormone replacement therapy. EMBO Reports (European Molecular Biology Organization) 2009; 10:108-13.
  • Partridge B, Underwood M, Lucke J, Bartlett H, Hall WD. Ethical concerns in the community about technologies to extend human life span (Invited target article). American Journal of Bioethics 2009; 9:68-76.
  • Partridge B, Hall WD, Lucke J, Underwood M, Bartlett H. Mapping community concerns about radical extensions of human life expectancy. American Journal of Bioethics 2009; 9:W4-5.
  • Hall WD, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009; 374:1383-91.
  • Degenhardt L, Randall D, Hall WD, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. Drug and Alcohol Dependence 2009; 105:9-15.
  • Burns L, Randall D, Hall WD, Law M, Butler T, Bell J, Degenhardt L. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: Patient characteristics and patterns and predictors of treatment retention. Addiction 2009; 104:1363-72.
  • Hall WD. The adverse health effects of cannabis use: What are they, and what are their implications for policy? International Journal of Drug Policy 2009; 20:458-66.
  • Hall WD, Gartner C. Supping with the Devil? The role of law in promoting tobacco harm reduction using low nitrosamine smokeless tobacco products. Public Health 2009; 123:287-91.
  • Gartner C, Barendregt J, Hall WD. Predicting the future prevalence of cigarette smoking in Australia: how low can we go and by when? Tobacco Control 2009; 18:183-89.
  • Singleton J, Degenhardt L, Hall WD, Zabransky T. Mortality among amphetamine users: A systematic review of cohort studies. Drug and Alcohol Dependence 2009; 105:1-8.
  • Hall WD, Degenhardt L, Teesson M. Understanding comorbidity between substance use, anxiety and affective disorders: Broadening the research base. Addictive Behaviors 2009; 34:526-30.
  • Charlson F, Degenhardt L, McLaren J, Hall WD, Lynskey M. A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiology and Drug Safety 2009; 18:93-103.
  • Gartner C, Barendregt J, Hall WD. Multiple genetic tests for susceptibility to smoking do not outperform simple family history. Addiction 2009; 104:118-26.
  • Degenhardt L, Whiteford H, Hall WD, Vos T. Estimating the burden of disease attributable to illicit drug use and mental disorders: What is ‘Global Burden of Disease 2005’ and why does it matter? Addiction 2009; 104:1466-71.
  • Hall WD, Lynskey M. The challenges in developing a rational cannabis policy. Current Opinion in Psychiatry 2009; 22:258-62.
  • Degenhardt L, Hall WD, Lynskey M, McGrath J, McLaren J, Calabria B, Whiteford H, Vos T. Should burden of disease estimates include cannabis use as a risk factor for psychosis?. PLoS Medicine (Public Library of Science) 2009; 6:e1000133.
  • Henderson S, Andrews G, Hall WD. State of the nation’s mental health 2007. Australian and New Zealand Journal of Psychiatry 2009; 43:591-93.
  • Doran C, Shakeshaft A, Hall WD, Petrie D. Alcohol industry and government revenue derived from underage drinking by Australian adolescents, 2005. Addictive Behaviors 2009; 34:75-81.
  • Hall WD. Challenges in reducing cannabis-related harm in Australia. Drug and Alcohol Review 2009; 28:110-16.
  • Page A, Taylor R, Hall WD, Carter G. Mental disorders and socioeconomic status: Impact on population risk of attempted suicide in Australia. Suicide and Life-Threatening Behavior 2009; 39:471-81.
  • Gartner C, Hall WD. Smokeless tobacco use in Australia. Drug and Alcohol Review 2009; 28:284-91.
  • Gossop M, Hall WD. Clashes between the government and its expert advisers: Advisers need clear rules on how to express contrary views. British Medical Journal 2009; 339:b4662.
  • Carter A, Capps B, Hall WD, eds. Addiction neurobiology: Ethical and social implications EMCDDA Monograph. Lisbon: European Monitoring Centre for Drugs and Drug Addiction, 2009: 123-28.
  • Hall WD, Degenhardt L. The Australian Illicit Drug Reporting System: Monitoring trends in illicit drug availability, use and drug-related harm in Australia 1996-2006. Contemporary Drug Problems (Carmel, New York) 2009; 36:643-61.
  • Lucke J, Hall WD, Ryan B, Owen N. The implications of genetic susceptibility for the prevention of colorectal cancer: A qualitative study of older adults’ understanding. Community Genetics (now Public Health Genomics) 2008; 11:283-88.
  • Hall WD, Degenhardt L. Cannabis use and the risk of developing a psychotic disorder). World Psychiatry 2008; 7:68-71.
  • Degenhardt L, Hall WD. The adverse effects of cannabinoids: Implications for use of medical marijuana. Canadian Medical Association Journal 2008; 178:1685-86.
  • Hall WD, Gartner C, Carter A. The genetics of nicotine addiction liability: Ethical and social policy implications. Addiction 2008; 103:350-59.
  • Spriggs M, Olsson C, Hall WD. How will information about the genetic risk of mental disorders impact on stigma? Australian and New Zealand Journal of Psychiatry 2008; 42:214-20.
  • Gartner C, Hall WD. Should Australia lift its ban on low nitrosamine smokeless tobacco products?. Medical Journal of Australia 2008; 188:44-46.
  • Carter A, Hall WD. Informed consent to opioid agonist maintenance treatment: Recommended ethical guidelines (Policy analysis). International Journal of Drug Policy 2008; 19:79-89.
  • Hall WD, Chikritzhs T, d’Abbs P, Room R. Alcohol sales data are essential for good public policies towards alcohol (Editorial). Medical Journal of Australia 2008; 189:188-89.
  • Hall WD. The contribution of research to the development of a national cannabis policy in Australia. Addiction 2008; 103:712-20.
  • Degenhardt L, Roxburgh A, Van Beek I, Hall WD, Robinson M, Ross J, Mant A. The effects of the market withdrawal of temazepam gel capsules on benzodiazepine injecting in Sydney, Australia. Drug and Alcohol Review 2008; 27:145-51.
  • Hall WD, West R. Thinking about the unthinkable: A de facto prohibition on smoked tobacco products (editorial). Addiction 2008; 103:873-74.
  • Pham B, Hall WD, Hill P, Rao C. Analysis of socio-political and health practices influencing sex ratio at birth in Viet Nam. Reproductive Health Matters 2008; 16:176-84.
  • Lutsenko H, Doran C, Hall WD. Australian smokers’ use of bupropion and nicotine replacement therapies and their relation to reimbursement, Australia 2001-05. Drug and Alcohol Review 2008; 27:160-64.
  • Morley K, Hall WD. Explaining the convergence of male and female smoking prevalence in Australia. Addiction 2008; 103:487-95.
  • Hall WD, Mattick R. Oral substitution treatments for opioid dependence. Lancet 2008; 371:2150-51.
  • Hall WD, Capps B, Carter A. The use of depot naltrexone under legal coercion: The case for caution. Addiction 2008; 103:1922-24.
  • Degenhardt L, Hall WD. Australian heroin seizures and the causes of the 2001 heroin shortage: Response. International Journal of Drug Policy 2008; 19:293-94.
  • Hall WD. Assessing the population health impact of cannabis use. In: Sznitman S, Olsson B, Room R, eds. A cannabis reader: Global issues and local experiences EMCDDA Monograph. Lisbon: European Monitoring Centre on Drugs and Drug Addiction, 2008: 157-71.
  • Degenhardt L, Gibson A, Mattick R, Hall WD. Depot naltrexone use for opioid dependence in Australia: Large-scale use of an unregistered medication in the absence of data on safety and efficacy. Drug and Alcohol Review 2008; 27:448-49.
  • Underwood M, Bartlett H, Hall WD. Community attitudes to the regulation of life extension. Annals of the New York Academy of Sciences 2007; 1114:288-99.
  • Hall WD, Lucke J. Assessing the impact of prescribed medicines on health outcomes. Australia and New Zealand Health Policy 2007; 4:1.
  • Gartner C, Hall WD, Vos T, Bertram M, Wallace A, Lim S. Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study. Lancet 2007; 369:2010-14.
  • Patton GC, Coffey C, Lynskey MT, Reid S, Hemphill S, Carlin JB, Hall WD. Trajectories of adolescent alcohol and cannabis use into young adulthood. Addiction 2007; 102:607-15.
  • Hall WD, Degenhardt L. Prevalence and correlates of cannabis use in developed and developing countries. Current Opinion in Psychiatry 2007; 20:393-97.
  • Gartner CE, Hall WD, Chapman S, Freeman B. Should the health community promote smokeless tobacco (snus) as a harm reduction measure? PLoS Medicine (Public Library of Science) 2007; 4:1138-41.
  • Gibson AE, Degenhardt LJ, Hall WD. Opioid overdose deaths can occur in patients with naltrexone implants. Medical Journal of Australia 2007; 186:152-53.
  • Lubman DI, Yucel M, Hall WD. Substance use and the adolescent brain: A toxic combination? Journal of Psychopharmacology 2007; 21:792-94.
  • Partridge B, Hall WD. The search for Methuselah: should we endeavour to increase the maximum human lifespan? EMBO Reports (European Molecular Biology Organization) 2007; 8:888-91.
  • Hall WD. A research agenda for assessing the potential contribution of genomic medicine to tobacco control. Tobacco Control 2007; 16:53-58.
  • Hall WD, Degenhardt L. Regulating opioid prescribing to provide access to effective treatment while minimizing diversion: an overdue topic for research. Addiction 2007; 102:1685-88.
  • Hall WD. Psychoactive drugs of misuse: rationalising the irrational. Lancet 2007; 369:972-72.
  • Hall WD, Homel R. Reducing cannabis-impaired driving: Is there sufficient evidence for drug testing of drivers? Addiction 2007; 102:1918-19.
  • Degenhardt L, Hall WD. The relationship between cannabis and psychosis: epidemiological evidence and biological plausibility. Advances in Schizophrenia and Clinical Psychiatry 2007; 3:2-7.
  • Degenhardt L, Tennant C, Gilmour S, Schofield D, Nash L, Hall WD, McKay D. The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychological Medicine 2007; 37:927-34.
  • Degenhardt L, Hall WD. Is cannabis use a contributory cause of psychosis? Canadian Journal of Psychiatry 2006; 51:556-65.
  • Hall WD. Stereotactic neurosurgical treatment of addiction: minimizing the chances of another ‘great and desperate cure’. Addiction 2006; 101:1-3.
  • Hall WD. Is cannabis use psychotogenic? Lancet 2006; 367:193-95.
  • Hall WD. Cannabis use and the mental health of young people. Australian and New Zealand Journal of Psychiatry 2006; 40:105-13.
  • Hall WD. The mental health risks of adolescent cannabis use. PLoS Medicine (Public Library of Science) 2006; 3:159-62.
  • Hall WD. The regulatory challenges in engineering a safer tipple. Journal of Psychopharmacology 2006; 20:321-22.
  • Hall WD. How have the SSRI antidepressants affected suicide risk? Lancet 2006; 367:1959-62.
  • Hall WD. Minimising research censorship by government funders. International Journal of Drug Policy 2006; 17:240-41.
  • Hall WD. Ensuring that addiction science is deserving of public trust. Addiction 2006; 101:1223-24.
  • Hall WD. Avoiding potential misuses of addiction brain science. Addiction 2006; 101:1529-32.
  • Hall WD, Lucke J. How have the selective serotonin reuptake inhibitor antidepressants affected suicide mortality? Australian and New Zealand Journal of Psychiatry 2006; 40:941-50.
  • Hall WD, Room R. Assessing the wisdom of funding DrinkWise. Medical Journal of Australia 2006; 185:635-36.
  • Little M, Hall WD, Orlandi A. Delivering on the promise of human stem cell research: what are the real barriers? EMBO Reports (European Molecular Biology Organization) 2006; 7:1188-92.
  • Lucke J, Ryan B, Hall WD. What does the community think about lifespan extension technologies? The need for an empirical base for ethical and policy debates. Australasian Journal on Ageing 2006; 25:180-84.
  • Lucke JC, Hall WD. Strong and weak lifespan extension: what is most feasible and likely? Australasian Journal on Ageing 2006; 25:58-62.
  • Morley KI, Hall WD, Hausdorf K, Owen N. ‘Occasional’ and ‘social’ smokers: potential target groups for smoking cessation campaigns? Australian and New Zealand Journal of Public Health 2006; 30:550-54.
  • Degenhardt L, Day C, Gilmour S, Hall WD. The “lessons” of the Australian “heroin shortage” Substance Abuse Treatment, Prevention, and Policy 2006; 1:11.
  • Degenhardt L, Hall WD, Warner-Smith M. Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sexually Transmitted Infections 2006; 82:III56-III63.
  • Gilmour S, Degenhardt L, Hall WD, Day C. Using intervention time series analyses to assess the effects of imperfectly identifiable natural events: a general method and example. BMC Medical Research Methodology 2006; 6:16.
  • Day C, Degenhardt L, Hall WD. Documenting the heroin shortage in New South Wales. Drug and Alcohol Review 2006; 25:297-305.
  • Day C, Degenhardt L, Hall WD. Changes in the initiation of heroin use after a reduction in heroin supply. Drug and Alcohol Review 2006; 25:307-13.
  • Hall WD, Degenhardt L. What are the policy implications of the evidence on cannabis and psychosis? Canadian Journal of Psychiatry 2006; 51:566-74.
  • Hall WD, Kimber J. Being realistic about benefits of supervised injecting facilities. Lancet 2005; 366:271-72.
  • Hall WD. British drinking: a suitable case for treatment? British Medical Journal 2005; 331:527-28.
  • Hall WD. The prospects for tobacco harm reduction. International Journal of Drug Policy 2005; 16:139-42.
  • Hall WD. Will nicotine genetics and a nicotine vaccine prevent cigarette smoking and smoking-related diseases? PLoS Medicine (Public Library of Science) 2005; 2:860-63.
  • Hall WD, Christie M, Currow D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncology 2005; 6:35-42.
  • Hall WD, Lynskey M. Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug and Alcohol Review 2005; 24:39-48.
  • Hall WD, Ward R, Liauw WS, Brien JE, Lu CY. Tailoring access to high cost, genetically targeted drugs. Medical Journal of Australia 2005; 182:607-08.
  • Lucke JC, Hall WD. Who wants to live forever? EMBO Reports (European Molecular Biology Organization) 2005; 6:98-102.
  • Degenhardt L, Day C, Dietze P, Pointer S, Conroy E, Collins L, Hall WD. Effects of a sustained heroin shortage in three Australian States. Addiction 2005; 100:908-20.
  • Degenhardt LJ, Conroy E, Gilmour S, Hall WD. The effect of a reduction in heroin supply on fatal and non-fatal drug overdoses in New South Wales, Australia. Medical Journal of Australia 2005; 182:20-23.
  • Teesson M, Degenhardt L, Proudfoot H, Hall WD, Lynskey M. How common is comorbidity and why does it occur? Australian Psychologist 2005; 40:81-87.
  • Degenhardt L, Conroy E, Day C, Gilmour S, Hall WD. The impact of a reduction in drug supply compliance with treatment for drug on demand for and dependence. Drug and Alcohol Dependence 2005; 79:129-35.
  • Degenhardt L, Day C, Gilmour S, Hall WD. Patterns of illicit drug use in NSW, Australia following a reduction in heroin supply. International Journal of Drug Policy 2005; 16:300-07.
  • Degenhardt L, Day C, Conroy E, Gilmour S, Hall WD. Age differentials in the impacts of reduced heroin: effects of a “heroin shortage” in NSW, Australia. Drug and Alcohol Dependence 2005; 79:397-404.
  • Degenhardt L, Reuter P, Collins L, Hall WD. Evaluating explanations of the Australian ‘heroin shortage’. Addiction 2005; 100:459-69.
  • Hall WD. Retrospections of a recovering drug researcher. Addiction 2004; 99:153-54.
  • Hall WD. The psychotogenic effects of cannabis use: challenges in reducing residual uncertainties and communicating the risks. Addiction 2004; 99:511-12.
  • Hall WD. The contribution of research to Australian policy responses to heroin dependence 1990-2001: a personal retrospection. Addiction 2004; 99:560-69.
  • Hall WD. Feeling ‘better than well’: can our experiences with psychoactive drugs help us to meet the challenges of novel neuroenhancement methods? EMBO Reports (European Molecular Biology Organization) 2004; 5:1105-09.
  • Hall WD, Carter L. Ethical issues in using a cocaine vaccine to treat and prevent cocaine abuse and dependence. Journal of Medical Ethics 2004; 30:337-40.
  • Hall, W. and Carter, L. (2004) Ethical implications of using a cocaine vaccine to treat and prevent cocaine dependence, Journal of Medical Ethics, 30, 337-340.
  • Hall, W. (2004) The Australian policy debate about embyronic stem cell research, Health Law Review, 12, 27-33.
  • Hall, W (2004) The contribution of research to Australian policy responses to heroin deendence 1990-2001: a personal retrospection, Addiction, 99, 560-569.
  • Morely, K., Hall, W. and Carter, L. (2004) Genetic screening for susceptibility to depression: can we and should?, Australian and New Zealand Journal of Psychiatry, 38, 73-80.
  • Morely, K. and Hall, W. (2004) Pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations, 82, 21-30.
  • Hall, W., Morley, K. and Lucke, J. (2004) Teh prediction of disease risk in genomic medicine: scientific prospects and implications for public policy and ethics, EMBO Reports, 5, S22-S26.
  • Hall, W. (2004) Neuroscience research on the addictions: a prospectus for future ethical and policy analysis, Addictive Behaviors, 29, 1481-1495.
  • Taylor, R. and Hall, W. (2003) Respiratory heallth effects of cannabis: position statement of the Thoracic Society of Australia and New Zealand, Internal Medicine Journal, 33, 310-313.
  • Hall, W, Mant, A,, Rendell, Donnelly, N. , Mitchell, P. , McManus, P., and Hickey, I. (2003) Association between antidepressant prescribing and suicide in Australia 1991-2000: trend analysis, British Medical Journal, 326, 1008-1012.
  • Hall, W. and Degenhardt, L. (2003) Medical marijuana initiatives: Are they justified? How successful are they likely to be? , CNS Drugs.
  • Hall, W and Pacula, R. (2003) Cannabis Use and Dependence: Public Health and Public Policy. Melbourne: Cambridge University Press.
  • Morley, K and Hall, W. (2003) Is there a genetic susceptibility to engage in criminal acts?, Trends and Issues in Criminology, 263, 1-6.
  • Hall, W, Carter, L., and Morley, K. (2003) Addiction, neuroscience and ethics, Addiction, 98, 867-870.
  • Hall, W. and MacPhee, D. (2002) Cannabis Use and Cancer, Addiction 97:243-247.
  • Teesson, M., Degenhardt, L. and Hall, W. (2002) Addictions. Clinical Psychology: A Modular Course. London: Psychology Press.
  • Hall, W., Lynskey, M. and Madden, P. (2002) The Genetics of Tobacco Use: Methods, findings and Policy Implications, Tobacco Control 11:119-124.
  • Hall, W (2002) The Prospects for Immunotherapy in Smoking Cessation, Lancet 360:1089-1091.
  • Hall, W. (2001) Reducing the Harms of Cannabis Use: The Policy Debate in Australia, Drug and Alcohol Dependence 62:163-174.
  • Hall, W. Degenhardt, L., and Lynskey, M. (2001) National Drug Strategy Monograph No. 44. Canberra: Commonwealth Department of Health and Aged Care.

Contact

Contact Information

Academy of the Social Sciences in Australia

    ABN: 59 957 839 703
  • Location: 26 Balmain Crescent, Acton, ACT 2601
  • Postal: GPO Box 1956, Canberra, ACT 2601
  • +61 .2 62491788
  • +61 .2 62474335
  • secretariat@assa.edu.au